ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OXB Oxford Biomedica Plc

201.00
3.80 (1.93%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.80 1.93% 201.00 199.20 203.50 202.50 194.20 199.00 240,015 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medicinal Chems,botanicl Pds 139.99M -45.16M -0.4676 -4.31 194.61M
Oxford Biomedica Plc is listed in the Medicinal Chems,botanicl Pds sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 197.20p. Over the last year, Oxford Biomedica shares have traded in a share price range of 164.40p to 473.00p.

Oxford Biomedica currently has 96,580,639 shares in issue. The market capitalisation of Oxford Biomedica is £194.61 million. Oxford Biomedica has a price to earnings ratio (PE ratio) of -4.31.

Oxford Biomedica Share Discussion Threads

Showing 21151 to 21173 of 26425 messages
Chat Pages: Latest  853  852  851  850  849  848  847  846  845  844  843  842  Older
DateSubjectAuthorDiscuss
21/6/2022
11:32
Having been reading badger60 articles on this forum I thought to myself self I am going to end it now and commit suicide 😭😭 than I read Harry's article's than I think to myself hanging on boy we are on the way up and their is a lot to live for 🤣🤣
Great articles harry as always.

you for me
21/6/2022
11:14
Dominic, I can confirm that there is a note out this morning from a leading investment bank , confirming that the vector in YTB323 is OXB's Lentivector , so this should be important and excellent news for us .
As an aside they give an updated price target of £10.60 .


Tuco.

tuco 1
21/6/2022
11:07
I can confirm that they ARE using our lenti. That knowledge now explains why we were agreeing to supply less volume but are free to use elsewhere. The method implies less volume inherently will be needed per patient, but numbers of patients should grow, and therefore royalties should be bigger.
dominiccummings
21/6/2022
10:52
Whist we're all in a more upbeat mood today - share price climbing, lovely weather, summer solstice and first day of the druid shooting season, can I take the opportunity to remind us all of a positive here which may well come under the category of elephant in the room:-

We have a long and fruitful relationship with Novartis, being a key / essential supplier to their first in man / first approved CAR-T with our LentiVector which is tied to their licence / approval.

Novartis are about to move up a gear with T-Charge in their next generation CAR-T and if anyone remembers the Novartis presentation slide that I linked to in my post 3321 then they say clearly that they are using the same vector as Kymriah (i.e. ours)



Look at the last line from the top banner (below)

INTRODUCTION
• Extended T-cell culture periods in vitro deplete the chimeric antigen receptor (CAR)-T cell final product of naive and stem cell memory T-cell (Tscm) subpopulations that are associated with improved antitumor efficacy1
• YTB323 is an investigational, autologous CD19-directed CAR-T cell therapy – YTB323 expresses the same validated CAR as tisagenlecleucel (Kymriah®), an approved CAR-T cell therapy for pediatric/young adult B-cell acute lymphoblastic leukemia (B-ALL) and relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)2,3 – YTB323 is produced using a simplified and innovative platform called T-Charge™, which reduces the manufacturing process time to <2 days
• The new T-Charge™ manufacturing platform was evaluated in a preclinical setting compared to traditional manufacturing (TM) of a CAR-T product using the same lentiviral vector (CTL*019)

harry s truman
21/6/2022
08:42
Things tend to come right as long as the company is fully funded, well managed etc. There is the old adage it’s time in the market not necessarily timing.
chillpill
21/6/2022
08:29
I'm pleased for you with that CP.

I realise that there are more investment mantras than can fit into one very big book, but most of them revolve around the idea that if you are patient then a decent stock will come good (eventually).

There are some videos which are stuck at a certain point in time now (for obvious reasons) but I always enjoy listening to the YouTube speeches where Peter Lynch is reminiscing on life and his time in charge of Magellan (29% average annual return over a 20+ year period). Quite humorous but a lot of common sense in there.

Even with all the information available at a click today, the market still does greed and fear. If you can hold fast during the fear phase then it's usually ok.

harry s truman
21/6/2022
07:58
One of the more bizarre investments I made was in William Hill. I bought it in Jan 2020 as a steady growth stock with yield at 180p.
Covid struck. Price fell. Went out of the index. Stock briefly hit 20p and within 4 months it was bid for at 272p.

I managed to average down a bit at 40p but was complete madness.

Fortunately I made decent money in the end!

chillpill
21/6/2022
07:18
Buying after the forced selling by index funds generally works especially if the fundamentals remain the same.

I agree it could bounce to £6 quite quickly.

chillpill
20/6/2022
19:43
Could be a dead cat but i doubt it.Should retest 6 quid at a minimunm
steeplejack
20/6/2022
19:09
Harry I totally arree with almost everything you said.....but I did post a while back before the crash about our over perceived reliance on covid stuff and to focus on ground breaking core science cart t ect I didn't sell as price dropped and are here for long term...never a better time to buy!!
timax333
20/6/2022
17:48
tim,

God bless you for the no bad news bit there, but there are more things than I can shake a stick at which have battered us over the last 9 months. Just a few here -

Number 1 has to be that almost everybody external to OXB sees us primarily as a coronavirus vaccine company and seemed genuinely shocked that the work for AZ would tail off. None of our analysts include AZ coronavirus work in their valuations, but that was the only headline from our best ever results which went around the world and (I think) prompted our biggest ever percentage drop on results presentation day. How many more can you remember when the Chairman / acting CEO has to open by clarifying what the headline of the press release meant at the beginning of the presentation?

Novartis changed their LentiVector supply contract at our request. Unfortunately the market read the Novartis release as being that they wouldn't be needing as much LentiVector and not that OXB were regaining exclusive rights and giving non-exclusive rights because they could.

Sio handed our Parkinson's drug back - ostensibly because with speed of patient recruitment vs cashburn meaning they would never get there, but nobody external to OXB will see a returned drug being anything other than rejected. Even the friendly analysts know it means no more milestones / stage payments from them.

OXB made a major investment and biggest ever spend right at the point the tech market chose to fold in on itself. OK, we know things are fine, that we can pay the loan and that we are moving into a very good position with regard to future co-development and manufacturing of multiple vector types. Everybody else saw the abridged version of that - big spend and loan during downturn

JD's retirement will be seen in all kinds of ways, but in reality he just wants to retire.

And it goes on, but all this with an impending property bubble collapse in China, a war in the Ukraine energy shock and inflation in double figures because our dear leaders thought they could defeat a chest infection by outspending it.

I'm not for a minute suggesting that OXB wouldn't have dropped without this, but I am suggesting that the fall would have been nowhere near as steep.

harry s truman
20/6/2022
17:17
fh,

With my usual caveat here that I don't understand this, then back in 2016 when this paper was written then it seems that someone at OXB was working on herpesvirus research.



Whether this is related to that tweet or not I don't know.

harry s truman
20/6/2022
17:10
Hi harry....its gone up 30p on no good news....Wow. it went down more than £ 12 on no bad news...its just the chaotic world we live in....its will probably take 3 years to get back where we were 6 months ago....but keep the faith ...brilliant future mid to long term
timax333
20/6/2022
15:35
as I said last week, you want to buy Friday close or on Monday. this was obvious.
Now to those shorts, most likely work for hedge funds, the recovery will be swift and you may see a bid coming.
we alresdy seen Pfizer taking a stake in another vaccine company this morning. that's how large pharma / buotechs function. they acquire and acquire and acquire PLATFORMS.
Buy the Sale!

qnq
20/6/2022
14:57
CP,

Up 7.6% on no news? So unless there's something in the background here you were obviously correct with your post last week regarding rebalancing.

===

chillpill 16 Jun '22 - 22:15 - 3333 of 3367

The main reason for the fall is that it is now out of the FTSE 250. It was announced at the start of the month. All rebalancing has to be done by tomorrow’s close.
Generally stocks bounce after this forced selling happens.

harry s truman
20/6/2022
13:54
I think just commenting, but maybe we are . Krystal Biotech involved here but unless we have collaborated with them . Not clear. OXB tweeting makes you wonder though
fhasson
20/6/2022
13:46
Where we (Oxb) just commenting on that report from the tweet, or are we involved in manufacture I wonder?
philh75
20/6/2022
13:42
https://twitter.com/oxfordbiomedica/status/1538875803622072320?s=21&t=EZ_A6lkFGxqUEdH6YvLZSw
fhasson
20/6/2022
13:17
Seems to be headed in an opposite direction to your guesses bodger
dominiccummings
20/6/2022
12:45
CP,

EBV is a herpes virus,infects about 95% of adults, but very few will develop MS.

marcusl2
20/6/2022
10:18
I’m not so sure UK property will take much of a hit.Money has to find a home.The FTSE is lower today than at the turn of the millennium.Property is the ultimate long term investment.Also,if the 1970s is anything to go by,the Lab/LiberalDemocrat coaltion lurking in the wings will inevitably screw the property market up.They’ll impose all sorts of further dictates on the rental market,landlords will withdraw properties from the market distorting supply and demand.Property prices will “cool off” for sure but i don’t see a crash.
steeplejack
20/6/2022
10:05
Don’t something like 90% of the population infected with Epstein-Barr?

I found out a couple of years ago I had contracted it some stage

chillpill
20/6/2022
08:07
Interesting study.

Scott Gottlieb, MD
🧵We always saw Epstein Barr Virus as reality of growing up, many teenagers got it. We never thought of vaxxing for it. Now we know it causes B cell cancers and probably MS. We may well vaccinate for it in future, just like we now vaccinate for HPV 1/2

marcusl2
Chat Pages: Latest  853  852  851  850  849  848  847  846  845  844  843  842  Older

Your Recent History

Delayed Upgrade Clock